January 2021 marks the first anniversary of the start of the COVID-19 global pandemic and the world is still struggling in containing the spread of the disease with ongoing surges of infection in many countries. In the previous two APRU Crisis Management Webinars, distinguished faculty members and guests discussed epidemiological and policy aspects of the COVID-19 pandemic. At this critical juncture, more efforts are needed from governments, international organizations, private sectors, research institutions and other stakeholders to support and develop new technologies and products. One of the most inspiring news nowadays is the potential success of COVID-19 vaccine development.
The upcoming third APRU Public Health Crisis Management Webinar, in collaboration with four APRU universities (Peking University, University of California Los Angeles, University of Sydney, and National University of Singapore), and led by the Peking University School of Public Health, will focus on potential solutions for COVID-19 pandemic control. In this webinar, speakers will review progresses and challenges facing, the development and application of the new technologies and products for controlling COVID-19 pandemic, discuss the strategies and measures which have been implemented, share lessons learned and offer future directions from broad perspectives.
Solutions for COVID-19 Pandemic Control: Vaccines and Beyond
Date and Time
17:00-19:00 January 12, 2021 (Los Angeles)
9:00-11:00 January 13, 2021 (Beijing, Hong Kong and Singapore)
12:00-14:00 January 13, 2021 (Sydney)
|Prof. Zhi-Jie Zheng, MD, MPH, PhD, School of Public Health, Peking University
Zhi-Jie Zheng is a University Endowed Chair Professor and Head of the Department of Global Health, School of Public Health, Peking University (PKU), Beijing, China. His research focuses on epidemiology and prevention strategies for diseases of major public health concerns, emergency medical system development and policy, public health emergency preparedness and responses, and global health strategies and governance.
|Dr. Hannah Clapham, MSc, PhD, Saw Swee Hock School of Public Health, National University of Singapore
Talk title: Vaccination for COVID-19, aims and strategies for use.
Dr. Hannah Clapham is Assistant Professor at NUS Saw Swee Hock School of Public Health, and was previously Head of Mathematical Modelling Group at the Oxford University Clinical Research Unit (OUCRU), University of Oxford. She has a particular interest in vector-borne diseases, such as dengue, and vaccine preventable diseases. For COVID-19, Dr. Clapham has been working on modelling the spread nationally and globally, as well as modelling the optimal use of control measures, including vaccination.
|Dr. Jesse Clark, MD, MSc, David Geffen School of Medicine, University of California Los Angeles
Talk title: COVID-19 vaccine research in the US: state of the science
Jesse Clark, MD, MSc, is Associate Professor-in-Residence in the Department of Medicine, Division of Infectious Disease and Department of Family Medicine in the David Geffen School of Medicine at UCLA. His research addresses the integration of new prevention technologies within the social and sexual networks of Latin American and Latino MSM. He studied History and American Civilization at Brown University and Medicine at Albert Einstein College of Medicine, completed Internal Medicine Residency at Montefiore Medical Center, and Infectious Diseases Fellowship at UCLA. He is Director of the UCLA South American Program in HIV Prevention Research (SAPHIR) training program in Peru, Colombia and Brazil. Current research includes: Use of social networks to promote PrEP adherence among Transgender Women in Peru; Rectal STI screening as a strategy to identify and control HIV/STI transmission risks within MSM sexual networks in Peru; and Evaluation of sexual network patterns among Latino MSM in Los Angeles. Dr. Clark is Medical Director of the UCLA Vine Street Clinic and IOR for the site in the HVTN704/HPTN085 Antibody-Mediated Prevention (AMP) trial of monoclonal antibodies to prevent HIV acquisition, the HPTN 083 trial of injectable cabotegravir for pre-exposure prophylaxis among MSM and TW, and the CoVPN COVE trial of the Moderna mRNA -1273 vaccine.
|Dr Diego Silva, MA, PhD, School of Public Health, University of Sydney
Talk title: Public health ethics and COVID-19
Dr Diego S. Silva is a Lecturer in Bioethics at Sydney Health Ethics, University of Sydney School of Public Health. Previously, he was an Assistant Professor at Simon Fraser University in British Columbia, Canada (2015-2019). Diego's primary research interests include: public health ethics; infectious diseases ethics, primarily tuberculosis; complexity, systems thinking and ethics; microbiome and ethics; mental health ethics. Much of his current work is around ethics and COVID-19.
|Prof. Fuqiang Cui, MD, MPH, PhD, School of Public Health, Peking University
Talk title: The latest development of COVID-19 vaccine
Prof. Fuqiang Cui is the professor and Director of Vaccine Research Center, School of Public Health, Peking University. His research interests are infectious diseases, its epidemiology and prevention, mainly focuses on vaccine preventable diseases, epidemiological research on vaccines and vaccination, immunization intervention, international cooperation, global health.
This webinar is open to the public and will be recorded for those who cannot attend live.
Click the below images to find out the information of previous webinars.
APRU Disclaimer: The views, information, or opinions expressed during the Solutions for COVID-19 Pandemic Control: Vaccines and Beyond are solely those of the individuals involved and do not necessarily represent those of The Association of Pacific Rim Universities (“APRU”) and its employees. APRU is not responsible and does not verify for accuracy any of the information contained in the series.